NVO - Novo Nordisk A/S

NYSE - NYSE Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
Currency in DKK. All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue111,831,000111,696,000111,780,000107,927,000
Cost of Revenue17,617,00017,632,00017,183,00016,188,000
Gross Profit94,214,00094,064,00094,597,00091,739,000
Operating Expenses
Research Development14,805,00014,014,00014,563,00013,608,000
Selling General and Administrative33,313,00032,124,00032,339,00032,169,000
Non Recurring----
Others-1,444,000-1,333,000-1,105,000-657,000
Total Operating Expenses64,705,00062,729,00063,348,00061,308,000
Operating Income or Loss47,126,00048,967,00048,432,00046,619,000
Income from Continuing Operations
Total Other Income/Expenses Net489,000-287,000-634,000-3,136,000
Earnings Before Interest and Taxes47,126,00048,967,00048,432,00046,619,000
Interest Expense-85,000-90,000-65,000-67,000
Income Before Tax47,615,00048,680,00047,798,00043,483,000
Income Tax Expense8,987,00010,550,0009,873,0008,623,000
Minority Interest----
Net Income From Continuing Ops38,628,00038,130,00037,925,00034,860,000
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income38,628,00038,130,00037,925,00034,860,000
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares38,628,00038,130,00037,925,00034,860,000